As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about the role of PSMA-PET Imaging versus PSA. Prostate specific antigen (PSA) is a ...

Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, recurrence detection, and patient selection for radioligand therapy. Oliver Sartor, ...

Source: Getty Images The molecular imaging modality detects metastases earlier and more accurately compared with conventional imaging and has ushered in a new era in metastasis-directed therapy. PSMA ...

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients, a critical indicator of a ...

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

PSMA-PET quantification required labor-intensive semiautomated software not in routine use. The study enrolled a high-risk metastatic castration-resistant prostate cancer subgroup, limiting ...

8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). How low do you need to go? Association ...

Compared to conventional imaging techniques, prostate specific membrane antigen (PSMA) PET imaging provides superior detection of bone metastases in prostate cancer patients a critical indicator of a ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) detected metastatic disease in 46% of patients with high-risk prostate cancer previously classified as nonmetastatic by ...

Ga-68 PSMA-11 is a radioactive diagnostic agent that targets PSMA, a protein commonly expressed in prostate cancer. The approval expands RadioMedix’s precision nuclear medicine portfolio and supports ...